Optimizing CAR T-Cell Therapy in DLBCL With Community and Academic Perspectives - Episode 7
Experts discuss strategies for monitoring and managing cytokine release syndrome (CRS) and neurotoxicity, the influence of key takeaways from cohorts 4 and 6 of the ZUMA-1 trial on their practice, and how post- chimeric antigen receptor T-cell therapy (CAR T) follow-up care is managed between academic and community settings.
Video content above is prompted by the following: